256 related articles for article (PubMed ID: 22642935)
1. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Ezzat HM; Cheung MC; Hicks LK; Boro J; Montaner JS; Lima VD; Harris M; Leitch HA
Leuk Lymphoma; 2012 Dec; 53(12):2390-6. PubMed ID: 22642935
[TBL] [Abstract][Full Text] [Related]
2. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Evens AM; Hong F; Gordon LI; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Gospodarowicz M; Cheson BD; Stiff PJ; Advani R; Miller TP; Hoppe RT; Kahl BS; Horning SJ
Br J Haematol; 2013 Apr; 161(1):76-86. PubMed ID: 23356491
[TBL] [Abstract][Full Text] [Related]
4. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
5. MOPP, ABVD, or both to treat Hodgkin's disease.
Aisenberg AC
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
[No Abstract] [Full Text] [Related]
6. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
9. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
[TBL] [Abstract][Full Text] [Related]
11. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
12. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
Canellos GP
Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
[No Abstract] [Full Text] [Related]
13. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
14. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
15. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
16. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Delwail V; Jais JP; Colonna P; Andrieu JM
Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
[TBL] [Abstract][Full Text] [Related]
17. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in the treatment of Hodgkin's disease.
Canellos GP; Come SE; Skarin AT
Semin Hematol; 1983 Jan; 20(1):1-24. PubMed ID: 6189191
[No Abstract] [Full Text] [Related]
19. The role of chemotherapy in the management of early stage Hodgkin's disease.
Rosenberg SA
Hematol Oncol; 1984; 2(1):61-3. PubMed ID: 6203821
[No Abstract] [Full Text] [Related]
20. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
